Want to see JP:4892 full AI Analyst Report?
Top Page
Cyfuse Biomedical K.K.
(4892)
Select Model
Select Model
Rating:44Neutral
Price Target:
¥593.00
▲(0.51% Upside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak financial performance—large ongoing losses and persistent negative free cash flow despite a revenue rebound—implying high execution and financing risk. Technicals add pressure with the stock trading below major moving averages and a negative MACD, while valuation is constrained by a negative P/E and no provided dividend yield.
Positive Factors
Revenue Rebound
The sharp 2025 revenue rebound indicates renewed commercial activity for the company’s platform and related offerings. If this higher sales base persists, it could provide greater operating leverage and a foundation for improving the economics of the regenerative-medicine business.
Negative Factors
Persistent Deep Unprofitability
Extremely negative operating and net margins show that the current cost structure is far too large relative to revenue. Persistent losses across four years indicate that the revenue rebound has not yet translated into scalable profitability, creating substantial execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The sharp 2025 revenue rebound indicates renewed commercial activity for the company’s platform and related offerings. If this higher sales base persists, it could provide greater operating leverage and a foundation for improving the economics of the regenerative-medicine business.
Read all positive factors
Cyfuse Biomedical K.K. (4892) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.17B
Dividend YieldN/A
Average Volume (3M)30.11K
Price to Earnings (P/E)―
Beta (1Y)0.35
Revenue Growth364.72%
EPS Growth18.43%
CountryJP
Employees23
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-81.38
Shares Outstanding10,092,100
10 Day Avg. Volume32,770
30 Day Avg. Volume30,110
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.88
Price to Sales (P/S)22.48
P/FCF Ratio-8.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cyfuse Biomedical K.K. Business Overview & Revenue Model
Company Description
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeu...
How the Company Makes Money
Cyfuse Biomedical makes money primarily by commercializing its 3D cell assembly/bioprinting technology and related offerings. Key revenue streams include: (1) Sale or provision of access to its Regenova platform and associated hardware/systems use...
Cyfuse Biomedical K.K. Financial Statement Overview
Summary
Income Statement
14
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 305.90M | 231.00M | 54.45M | 61.11M | 374.48M | 708.25M |
| Gross Profit | 145.27M | 78.40M | 1.56M | -378.00K | 223.93M | 568.20M |
| EBITDA | -743.38M | -792.68M | -860.12M | -659.31M | -370.81M | 89.07M |
| Net Income | -795.91M | -763.84M | -872.24M | -589.21M | -473.96M | 142.91M |
Balance Sheet | ||||||
| Total Assets | 3.93B | 4.27B | 3.52B | 4.21B | 4.82B | 2.65B |
| Cash, Cash Equivalents and Short-Term Investments | 3.39B | 3.73B | 3.05B | 3.87B | 4.44B | 2.41B |
| Total Debt | 1.23B | 1.31B | 852.80M | 913.00M | 857.79M | 569.06M |
| Total Liabilities | 1.30B | 1.51B | 975.60M | 1.01B | 1.05B | 746.12M |
| Stockholders Equity | 2.62B | 2.76B | 2.54B | 3.20B | 3.77B | 1.90B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -581.93M | -768.16M | -581.77M | -631.87M | 161.54M |
| Operating Cash Flow | 0.00 | -534.79M | -760.55M | -562.30M | -403.60M | 161.54M |
| Investing Cash Flow | 0.00 | -397.56M | -8.64M | -19.47M | -430.67M | -50.58M |
| Financing Cash Flow | 0.00 | 1.26B | -52.01M | 18.24M | 2.66B | 229.21M |
Cyfuse Biomedical K.K. Technical Analysis
Positive
590.00
Price Trends
544.18
Positive
578.61
Positive
596.18
Positive
Market Momentum
11.96
Negative
69.81
Neutral
75.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4892, the sentiment is Positive. The current price of 590 is above the 20-day moving average (MA) of 562.95, above the 50-day MA of 544.18, and below the 200-day MA of 596.18, indicating a bullish trend. The MACD of 11.96 indicates Negative momentum. The RSI at 69.81 is Neutral, neither overbought nor oversold. The STOCH value of 75.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4892.
Cyfuse Biomedical K.K. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | ¥6.11B | 0.93 | ― | 3.74% | -11.16% | -21.80% | |
54 Neutral | ¥5.67B | -45.72 | ― | 3.18% | 0.60% | -131.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥7.92B | -8.71 | -53.67% | ― | 32.42% | 61.00% | |
44 Neutral | ¥6.17B | -7.51 | ― | ― | 364.72% | 18.43% | |
44 Neutral | ¥4.89B | -0.61 | ― | ― | -37.69% | 1.85% | |
41 Neutral | ¥3.73B | -1.46 | ― | ― | ― | -5.66% |
* Healthcare Sector Average
JP:4892
Cyfuse Biomedical K.K.
611.00
-2.00
-0.33%
JP:4597
Solasia Pharma KK
29.00
-8.00
-21.62%
JP:4539
Nippon Chemiphar Co., Ltd.
1,570.00
-11.81
-0.75%
JP:4582
Symbio Pharmaceuticals Limited
61.00
-85.00
-58.22%
JP:4883
Modalis Therapeutics Corporation
35.00
-55.00
-61.11%
JP:7079
WDB coco Co., Ltd.
2,541.00
-110.89
-4.18%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.